
About
Bioclonal is a biotechnology company focused on developing antibodies against challenging peptide targets, with a strong emphasis on Alzheimer’s disease. It serves pharma, biotech, and research partners from Zaragoza, Spain, and also develops products and proprietary R&D programs related to diagnostics and therapeutics.
Services
Custom antibody development
Develops custom antibodies against peptide epitopes, including project-specific strategy design, immunization, antibody generation, and initial validation for downstream applications.
Monoclonal antibody characterization and production
Provides monoclonal antibody characterization and production as part of its custom development offering.
Protein production
Alzheimer antibody catalog
Offers ready-to-use research antibodies designed for Alzheimer’s research applications, including Tau and Amyloid-beta related epitopes.
Proprietary Alzheimer R&D
Advances a lead program focused on pathological forms of Amyloid beta and dimeric Aβ1-42 species.
Alzheimer’s Program
Develops antibodies against pathological forms of Amyloid beta, including dimeric Aβ1-42 species.
Proprietary R&D
Advances internal antibody research focused on pathological forms of Amyloid beta and related disease-relevant structures.
Capabilities
- Processes
- Antibody
- Peptide
- Oligonucleotide
- Cell therapy
- ELISA
- Capacity
- Commercial scale
Industries served
- Biotech
- Pharma
- Research
- Diagnostics
- Biomanufacturing
Details
- Founded
- 2022
- Based in
- Zaragoza, Spain
- Serves
- Global
- General enquiry
- info@bioclonal.es on their site